Tetratherix

Tetratherix Net Margin

The Net Profit Margin of Tetratherix (TTX.AX) as of Oct 22, 2026 is -1,015.14 %. In the previous year, Net Profit Margin was -824.89 % — a change of 23.06% (lower).

Net Margin

-1,015.14 %

YoY

23.06%

Last updated:

Net Profit Margin of Tetratherix is 2026 -1,015.14 % . Net Profit Margin of Tetratherix was 2025 -824.89 % . It decreases by 23.06% lower compared to the previous year.

Tetratherix's net margin stands at -2,627.3%, down from -618.4% several years earlier.

The Tetratherix Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2023
-321.48 AUD
Jan 1, 2024
-295.72 AUD
Jan 1, 2025
-824.89 AUD
Jan 1, 2026
-1,015.14 AUD
The Tetratherix Net Margin history
YEARNet MarginYoY
-1,015.14 %+23.06%
-824.89 %+178.94%
-295.72 %-8.01%
-321.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tetratherix Stock analysis

What does Tetratherix do? Tetratherix Ltd. develops a biostealth fluid matrix for regenerative medicine, creating injectable products that form 3D matrices upon physiological temperature exposure. The company's biomaterial platform uses polymer programming for implantable solutions, with Tegenix and TegenEOS serving as carriers mixed with bone graft materials for dental, oral, and orthopedic applications. TetraDerm products address surgical incision sites to minimize scarring, while Tutelix functions as a spacer to mitigate radiation therapy side effects in prostate cancer. The firm's manufacturing center in Sydney handles cleanroom production of these medical solutions. The company's revenue streams come from selling Tegenix, TegenEOS, TetraDerm, and Tutelix products to healthcare providers, hospitals, and medical device distributors specializing in regenerative medicine. These products target clinical segments including dental procedures, orthopedic surgery, and oncology treatments. Tetratherix's injectable fluid matrix technology differentiates its offerings by enabling tissue integration without causing bodily damage during application, supporting its positioning in the regenerative medicine market. Tegenix and TegenEOS are marketed as complementary solutions for bone graft applications, while TetraDerm focuses on post-surgical scar reduction. Tutelix specifically addresses radiation therapy side effects in prostate cancer patients. The company's manufacturing center in Sydney ensures quality production of these medical products, which are distributed to healthcare professionals across dental, orthopedic, and oncology fields. Tetratherix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tetratherix stock

Net Profit Margin of Tetratherix is -1,015.14 % in 2026.

Net Profit Margin of Tetratherix changed from -824.89 % to -1,015.14 %, representing a 23.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Tetratherix since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Tetratherix with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Tetratherix

All Key Metrics — Tetratherix